SCTX raises $155.5M, starts STX-1150 first-in-human trial
SCTX initiated first-in-human trial for STX-1150, secured $155.5M via IPO/private placement, and received $25M+ in CIRM grants. Q2 2026 net loss narrowed to $6.5M on lower R&D expenses, with funding runway into H1 2029.